EORTC AISBL / IVZW Avenue Mounierlaan, 83/11 Brussel 1200 Bruxelles • Belgie Belgique +32 2 774 16 11
Intranet • Home

Past news - highlights

• EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer" (ENASCO) on 27-29 October 2011 (with a tutorial on 25-27 October 2011), Brussels, Belgium
• PRESS RELEASE: Pazopanib improves progression free survival in adults with certain soft tissue sarcomas
• PRESS RELEASE: Sylatron™ receives FDA approval based on the EORTC 18991 trial
• EFGCP-EORTC Workshop “How to Achieve a Successful New Trial Legislation” 4th July 2011, Brussels
• A report on a Conference on the Future of Independent Academic Clinical Research in Europe held on 2 September 2010 at the Royal Academy of Medicine, Brussels, Belgium with the support of the Belgian Presidency of the Council of the European Union
• Future of Independent Academic Clinical Research in Europe: Recommendations and Conclusions – Françoise Meunier
• 13th Joint ECCO-AACR-EORTC-ESMO Workshop Methods in Clinical Cancer Research will be held from 18-24 June 2011 in Waldhaus Flims, Switzerland
• PRESS RELEASES from the 22nd EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics", 16-19 November 2010 - Berlin, Germany
• EORTC Groups Annual Meeting (EGAM): 1-4 March 2011, Brussels, Belgium
• EORTC Affiliated Institutions and Departments 2010
• EORTC Annual Report 2009 - 2010
• Future of Independent Academic Clinical Research in Europe, 2 September 2010, Palais des Académies with the support of the Belgian Presidency of the Council of the European Union, Brussels, Belgium
• An article written by Pr. Meunier on the need for more academic research and the creation of a European Investigator-Driven Clinical Trials Fund appeared recently in Public Service Review: European Union: issue 19, pages 228-229
• EORTC Course on Quality of Life, Symptom Research and Patient Reported Outcomes in Cancer Clinical Trials: 25 - 27 November 2009: Program & Registration
• Presentation of E.A. Eisenhauer : "New Response Evaluation Criteria in Solid Tumors: REVISED RECIST GUIDELINE (Version 1.1)"
• EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer": 14-17 October 2009, Brussels, Belgium
• AACR-NCI-EORTC Symposium on "Molecular Targets and Cancer Therapeutics" : 15-19 November 2009, Boston (MA), USA
• New EORTC Board (2009 - 2012)
• EORTC Groups Annual Meeting (EGAM), Brussels, Belgium (18-20 March 2009), with a pre-EGAM EORTC PAMM Meeting on 17 March
• Press Releases of EORTC-NCI-AACR 2008
• ASCO-NCI-EORTC Annual Meeting on "Molecular Markers in Cancer", Hollywood, Florida, USA (30 October - 1 November 2008)
• Conference on "Impact on Clinical Research of European Legislation - ICREL" Brussels, Belgium (2 December 2008)
• 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics", Geneva, Switzerland (21 - 24 October 2008)
• EU funded FP7 ICREL project assessing the impact of the European Clinical Directive (2001/20/EC) on clinical research activities
• Report on the EORTC-CONTICANET-ICREL-ECRIN Workshop “Biomedical Research in Europe: Which Challenges and Solutions for Academic Sponsors?” May 21st, 2008, EORTC Headquarters, Brussels, Belgium
• New EORTC Policy for Producing EORTC Guidelines / Expert Opinions / Promotional Material on Cancer Care
• PRESS RELEASE: CTI announces that the EORTC Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma
• Press release: Long-Term Pegylated Interferon Alfa-2b Therapy In Stage III Melanoma Demonstrated Significant And Sustained Impact On Relapse-Free Survival - EORTC 18991 Phase III Study Results Published in The Lancet
• NEW: EORTC Annual Report 2008 - 2009 : Organisation Current Research and Strategies
• EORTC Bids Farewell to Dominique Eeckhoudt after 35 Years of Dedicated Service
• New ECIL-2 Guidelines for the Management of Bacterial, Fungal and Viral Infections
• A New Chapter Begins for the EORTC: a European Journal of Cancer NEWS: Volume 44, issue 3, 2008, pp. 329 - 331
• RECENT EORTC-NCI-ASCO Annual Meeting 2007 (15-17 Nov. 2007, Brussels, Belgium): HIGHLIGHTS : Presentations & Posters
• Professor Tanja Cufer presents “Challenges and Barriers to Academic Cancer Research” at recent EU conference in Brdo, Slovenia
• EORTC GU Group trial 30911: EORTC statistician Richard Sylvester awarded "Prize of the Congress President" for best presentation on clinical urology at the 23rd Annual EAU Congress in Milan, Italy 2008 
• EORTC Affiliated Institutions and Departments 2007
• Scientific Highlights: 2007 Annual AACR-NCI-EORTC Conference "Molecular Targets and Cancer Therapeutics"
• EORTC expert appointed Senior Editor of Expert Review of Pharmacoeconomics & Outcomes Research
• PRESS RELEASE related to ASTRO: Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma Multiforme
• New Cancer Targets, New Therapeutics and Clinical Trials Among Subjects of AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics San Francisco, October 22-26, 2007 (Press-Release, 22 October 2007)
• Deadline for registration: 1 November 2007 - EORTC - NCI - ASCO Tutorial Meeting, Brussels, Belgium (14 - 15 November 2007)
• Deadline for registration: 1 November 2007 - EORTC - NCI - ASCO Annual Meeting on "Molecular Markers in Cancer", Brussels, Belgium (15 - 17 November 2007) - Registration, Program & Practical Information

• EORTC Trial results show that Prophylactic Cranial Irradiation in Small Cell Lung Cancer significantly increases survival (16 August 2007)

• New guidelines for preventing and treating infectious diseases in leukemic patients published (13 August 2007)
• EORTC Highlights at ASCO 2007  (31 May 2007)
• Radiation Preferred Over Surgery for some Patients with Non-Small Lung Cancer
• EORTC Groups Annual Meeting (EGAM) 2007
• Results of the EORTC Radiation Oncology Group Trial 22921 published in the New England Journal of Medicine (September 14, 2006)
• 18th EORTC-NCI-AACR International Conference on "Molecular Targets and Cancer Therapeutics" (7-10 November 2006, Prague)
• European Medicines and Executive Agency (EMEA) extends drug-label based on results of the EORTC 24971 trial (06-10-2006)
• European Medicines Agency (EMEA) and US Food and Drug Administration (FDA) extend drug-label based on results of the EORTC 24971 trial (October 20 2006)
• 10 EORTC Abstracts (Posters and Oral Presentations) accepted for the ASCO Meeting
  2 – 6 June 2006 Atlanta, Georgia - US
• Guidelines to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
• Press Release : A genomic signature of 254 genes predicting clinical outcome in Primary Cutaneous Melanoma identified: Results published in April 5, 2006 issue of the Journal of the National Cancer Institute on behalf of EORTC Melanoma Group
• Message from the President (03/04/2006)
• Predict Recurrence and Progression in Patients with Stage Ta T1 Bladder Cancer: EORTC Risk Tables Software
• Princess Astrid of Belgium visits the headquarters of the EORTC (27 March 2006)
• Rituximab maintenance therapy dramatically improves survival for patients with lymphoma
• Complementary and Alternative Medicine (CAM) in oncology Seminar (23-24 February 2006, Brussels )
• PRESS RELEASE: Breakthrough in medical research: New chemotherapy gives hope to brain tumour patients.
  A clear improvement in survival demonstrated for glioblastoma
• PRESS RELEASE: FDA Approves temozolomide on EORTC data
• EORTC achievements at ASCO 2005
• Message from the President ( July 01, 2005)
• Trial 30891 from the EORTC Genito-Urinary Group received a CapCURE award